ESG stands for ‘environmental, social and governance’ – without a doubt a global mega trend, and even more so in the post Covid-19 world.
During this webinar, we will look at how a strong ESG proposition can create value. In particular, we will illustrate the value creation process by providing a framework tailored to the pharma value chain to describe the various options.
As pharmaceutical companies will transform to adapt to new requirements, other tax and regulatory changes will also need to be taken into account. This can be seen as constraints but also as opportunities if dealt with properly from the start. Finally, we will also focus on social factors and illustrate how diversity & inclusion can help you drive value creation in the pharma industry.
This webinar is not only addressed to tax and regulatory specialists, but also to R&D,supply chain, HR and other operational people interested in understanding how ESGcan drive value creation.
Monday, 20 September 2021
8:30 – 10:00am CEST
- ESG in the Pharma value chain
- Tax and regulatory update – Clinical trials & Commercial
- The S element – achieving business results by implementing strategic Diversity andInclusion initiatives into your value chain
- Interview with Dr. FIorian RegIi, Area Tax Director, Roche
Dr. Florian Regli, Tax Director, Roche
Erik Steiger, Partner, Leader ESG and Tax Reporting & Strategy, PwC
Dr. Sandra Ragaz, Partner, Leader Pharma & Life Science VAT & Regulatory, PwC
Flora Marin, Director, Transfer Pricing and Value Chain Transformation, PwC
Johannes (Joop) Smits, Director, People & Organisation, PwC